This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

No abstract

Euglycemic DKA (euDKA) is a serious side effect associated with SGLT2 inhibitors. We present a case euDKA in a patient on an SGLT-2 inhibitor likely precipitated by COVID-19 infection. We suspect that COVID-19 led to euDKA. We pose the question of whether these medications should be discontinued proactively.